Literature DB >> 11986280

Importance of M-protein C terminus as substrate antigen for serodetection of equine arteritis virus infection.

Célia Jeronimo1, Denis Archambault.   

Abstract

Equine arteritis virus (EAV), an enveloped positive-stranded RNA virus, is the prototype of the arterivirus group. In a previous paper (A. Kheyar, S. Martin, G. St.-Laurent, P. J. Timoney, W. H. McCollum, and D. Archambault, Clin. Diagn. Lab. Immunol. 4:648-652, 1997), we have shown that the unglycosylated membrane (M) protein, which is composed of 162 amino acids (aa), is a major target of equine antibody to EAV. In order to determine the antigenic regions of the M protein, the cDNA encoding the M protein of EAV was inserted into the procaryotic expression vector pGEX-4T-1 to produce recombinant glutathione S-transferase-M fusion protein. Various deletion mutant clones, which covered the entire sequence of the M protein, were then generated by inverse PCR and expressed in Escherichia coli to examine, by a Western blot assay, the antigenic reactivity of the clone-derived truncated M proteins with sera from horses either experimentally or naturally infected with EAV. Deletion of the hydrophobic N-terminal 87 aa did not abolish immune reactivity of the protein with serum antibodies to EAV, thereby demonstrating the antigenicity of the C-terminal region (aa 88 to 162) of the M protein. Further truncations of the M-protein C-terminal domain defined particular linear epitope-containing amino acid sequence regions. However, only the M-protein C-terminal region was readily recognized by all EAV-specific horse antisera tested in this study. Based on these findings, only the M-protein C-terminal polypeptide composed of aa 88 to 162 is necessary to identify horse serum antibodies specific to the EAV M protein. Thus, this polypeptide might be useful for serodetection of EAV-infected animals.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11986280      PMCID: PMC119998          DOI: 10.1128/cdli.9.3.698-703.2002

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  34 in total

1.  Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein.

Authors:  F Megret; J P Hugnot; A Falconar; M K Gentry; D M Morens; J M Murray; J J Schlesinger; P J Wright; P Young; M H Van Regenmortel
Journal:  Virology       Date:  1992-04       Impact factor: 3.616

2.  Fine mapping of virus-neutralizing epitopes on hepatitis B virus PreS1.

Authors:  C Y Maeng; C J Ryu; P Gripon; C Guguen-Guillouzo; H J Hong
Journal:  Virology       Date:  2000-04-25       Impact factor: 3.616

3.  Detection of antibodies to equine arteritis virus by a monoclonal antibody-based blocking ELISA.

Authors:  H J Cho; S C Entz; D Deregt; L T Jordan; P J Timoney; W H McCollum
Journal:  Can J Vet Res       Date:  2000-01       Impact factor: 1.310

4.  The open reading frame 3 of equine arteritis virus encodes an immunogenic glycosylated, integral membrane protein.

Authors:  J F Hedges; U B Balasuriya; N J MacLachlan
Journal:  Virology       Date:  1999-11-10       Impact factor: 3.616

5.  Use of peptide synthesis to probe viral antigens for epitopes to a resolution of a single amino acid.

Authors:  H M Geysen; R H Meloen; S J Barteling
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

6.  Identification of antigenic regions on VP2 of African horsesickness virus serotype 3 by using phage-displayed epitope libraries.

Authors:  L Bentley; J Fehrsen; F Jordaan; H Huismans; D H du Plessis
Journal:  J Gen Virol       Date:  2000-04       Impact factor: 3.891

7.  Development and evaluation of ELISA procedures to detect antibodies against the major envelope protein (G(L)) of equine arteritis virus.

Authors:  J Nugent; R Sinclair; A A deVries; R Y Eberhardt; J Castillo-Olivares; N Davis Poynter; P J Rottier; J A Mumford
Journal:  J Virol Methods       Date:  2000-11       Impact factor: 2.014

8.  Equine arteritis virus is not a togavirus but belongs to the coronaviruslike superfamily.

Authors:  J A den Boon; E J Snijder; E D Chirnside; A A de Vries; M C Horzinek; W J Spaan
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

9.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

10.  All subgenomic mRNAs of equine arteritis virus contain a common leader sequence.

Authors:  A A de Vries; E D Chirnside; P J Bredenbeek; L A Gravestein; M C Horzinek; W J Spaan
Journal:  Nucleic Acids Res       Date:  1990-06-11       Impact factor: 16.971

View more
  5 in total

1.  Characterization of equine humoral antibody response to the nonstructural proteins of equine arteritis virus.

Authors:  Yun Young Go; Eric J Snijder; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2010-12-08

2.  Development of a fluorescent-microsphere immunoassay for detection of antibodies specific to equine arteritis virus and comparison with the virus neutralization test.

Authors:  Yun Young Go; Susan J Wong; Adam J Branscum; Valerie L Demarest; Kathleen M Shuck; Mary L Vickers; Jianqiang Zhang; William H McCollum; Peter J Timoney; Udeni B R Balasuriya
Journal:  Clin Vaccine Immunol       Date:  2007-11-21

3.  Replication of Equine arteritis virus is efficiently suppressed by purine and pyrimidine biosynthesis inhibitors.

Authors:  José-Carlos Valle-Casuso; Delphine Gaudaire; Lydie Martin-Faivre; Anthony Madeline; Patrick Dallemagne; Stéphane Pronost; Hélène Munier-Lehmann; Stephan Zientara; Pierre-Olivier Vidalain; Aymeric Hans
Journal:  Sci Rep       Date:  2020-06-22       Impact factor: 4.379

Review 4.  Equine arteritis virus.

Authors:  Udeni B R Balasuriya; Yun Young Go; N James MacLachlan
Journal:  Vet Microbiol       Date:  2013-07-03       Impact factor: 3.293

5.  Binding of cellular proteins to the leader RNA of equine arteritis virus.

Authors:  Denis Archambault; Marie-Claude St-Louis; Stéphanie Martin
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.